About Us
Our Mission
Leadership
Partnerships
Careers
Contact Us
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
MARIO
Community Infections
Pipeline
Publications and Presentations
Product
News
News
Events
Careers
Investors
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
Invasive Fungal Infections
Invasive Candidiasis
Invasive Aspergillosis
MARIO
Community Infections
Vulvovaginal Candidiasis
Recurrent VVC
Pipeline
Publications and Presentations
Our Science
Publications and Presentations
Date
Title
April 2019
Efficacy of Ibrexafungerp (formerly SCY-078) Against
Pneumocystis
Pneumonia in a Murine Therapeutic Model.
Stephen A. Barat, Katyna Borroto-Esoda, David A. Angulo, Alan Ashbaugh, Melanie Cushion
ECCMID 2019
April 2019
Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases
Oliver A. Cornely MD, FECMM, FIDSA, FAAM, FACP
Consultant, Infectious Diseases
Director, European Mycology Excellence Center
University Hospital of Cologne
ECCMID 2019
April 2019
Successful Treatment of Two Patients with
Candida auris
Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study
D Juneja, O Singh, B Tarai, DA Angulo
ECCMID 2019
April 2019
Favourable Clinical Outcome of Two Patients with
Candida
spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study
Philipp Koehler, Oliver A. Cornerly, David Angulo
ECCMID 2019
March 2019
Ibrexafungerp: Activity against
Pneumocystis
S. Barat
Superbugs and Superdrugs 2019
September 2018
Ibrexafungerp (formerly SCY-078) Displays Potent
In Vitro
Activity Against
C. glabrata
Isolates with Mutations in
fks
Genes
Stephen Barat, Katyna Borroto-Esoda, David Angulo
ESCMID ASM 2018
June 2018
SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against
Candida, Aspergillus
and
Pneumocystis
spp.
Stephen Barat, Katyna Borroto-Esoda, David Angulo
ISHAM 2018
June 2018
In vitro
Activity of SCY-078 in Combination with Isavuconazole or Amphotericin B against Medically Important Moulds
V. Petraitis, P. Kavaliauskas, R. Planciuniene, M.Viragailis, R.Petraitiene, S.Barat, K. Borroto-Esoada, D. Angulo, T. Walsh
ASM Microbe 2018
February 2018
Combination Therapy with SCY-078 and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
V. Petraitis, S. Barat, K. Borroto-Esoda, D. Angulo, T. Walsh
AAA 2018
October 2017
SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
K. Borroto-Esoda, S. Barat, D. Angulo, C. Carruthers, K. Holden, P. Warn
IDWeek 2017
< Prev
Next >
Please ensure Javascript is enabled for purposes of
website accessibility